Nerium Biotechnology, Inc., (Nerium) is an international research and development company dedicated to offering solutions that are based on proven science. Nerium’s research and product development has focused on the anti-cancer, anti-viral, immune-stimulating, and dermal properties of natural botanical compounds for beneficial use in concert with leading medical research institutions.

From this research, Nerium has re-discovered, identified, and developed well-defined Nerium Extracts from the Nerium oleander plant, a plant which is known to contain cardiac glycosides (oleandrin). Utilizing proprietary extraction technologies; Nerium has been able to extract the active ingredients in a way that preserves the unique components and beneficial properties of this plant. Thus, Nerium is able to develop an ever expanding pipeline of the “first of its kind” Nerium Extract-based applications/products.

Dr. Robert A. Newman, Ph.D., Professor Emeritus, Professor of Experimental Therapeutics, Founder and Co-Director of the Pharmaceutical Development Center at the University of Texas M.D. Anderson Cancer Center (MDACC) serves as lead researcher and scientific advisor to Nerium Biotechnology, Inc. His initial characterization and pharmacology research on Nerium Extracts provides the bases for product development and quality control. He continues to assist with continuing FDA clinical trials with Nerium Extracts. (See Cancer Research)

Cardio Glycoside Historical use of the Nerium oleander plant for medicinal applications has been reported in ancient texts and folklore for more than 1500 years. The Nerium oleander plant has been used traditionally as folk remedies for a wide variety of maladies and conditions, including dermatitis, eczema, psoriasis, herpes, sores, abscesses, warts, corns, skin cancer, ringworm, scabies, epilepsy, abortifacients, asthma, malaria dysmenorrheal, emetics, diuretics and heart tonics.

History Of Cardiac Glycoside Use

Despite their potential to cause side effects, application of plants containing cardiac glycosides for treatment of malignant disease may extend back to Arab physicians in the 8th century. The potential use of cardenolide-like compounds for the treatment of cancer, initially investigated forty years ago, however, was abandoned because of the toxicity of these compounds.

It was only recently, that Scandinavian oncologists such as J. Haux have suggested that the apoptosis (cell death) produced by cardiac glycosides such as digitalis in human tumor cells occurred at concentrations that could be achieved without toxicity in humans and, therefore, this agent and plant extracts containing related cardiac glycosides (e.g. oleandrin from Nerium oleander) might be useful for treatment of cancer.

Nerium Oleander PlantWithin the past ten years there has been a substantial increase in the number of studies reported in peer-reviewed science journals that deal with the effects of cardiac glycosides on the growth of human malignant tumor cells. Our understanding of the spectrum of the pharmacologic activities of cardiac glycosides has increased significantly since the discovery of their effectiveness for treatment of congestive heart failure. It is now recognized that certain cardiac glycosides are involved in complex cell signal transduction mechanisms that may have important consequences in their application to the prevention and/or treatment of malignant diseases. Thus, it is reasonable to bring this history of the use of plant extracts containing cardiac glycosides to the point of clinical tests in patients with cancer.

To date, however, there are only two plant extracts containing cardiac glycosides (oleandrin) that have been developed for treatment of cancer and completed testing for safety in a Phase 1 clinical trial in the United States. The initial product was Anvirzel™, an aqueous extract of Nerium oleander and the second is PBI-02504, a super critical CO2 extract of Nerium oleander. The published conclusion for the Anvirzel™ Phase 1 clinical trial states: “Anvirzel™ can be safely administered at doses up to 1.2ml/m2/d (2.4cc). No dose limiting toxicities were found.” This study was conducted at the Cleveland Clinic in Cleveland, Ohio.

Note: In this trial maximum tolerated dose was limited to volume due to administration of Anvirzel™ by Intramuscular injection (IM).

PBI-02504 has recently completed testing for safety in a FDA Phase 1 clinical trial in the United States at M. D. Anderson Cancer Center in Houston, Texas. The publication of conclusions is in process and the initial findings (abstract) were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2011. The published conclusion will be available soon.

Note: Additional safety levels for oleandrin were reported. This trial provided for safety data at levels beyond the initial Anvirzel™ trial and at levels unexpected for oleandrin with no cardiac events.. Top

Nerium Research

Robert A. Newman, Ph.D.,
Scientific Advisor

Nerium Research

Latest News

September, 2011
Publication: In vitro and in vivo neuroprotective activity of the cardiac glycoside oleandrin...

August 2011
Press Release: Nerium SkinCare, Inc. and Nerium International, LLC (NeriumAD - Age-Defying Treatment)

July, 2011
NaturTech manufactures first commercial run of NeriumAD (Age –Defying Treatment / Night Cream)

July, 2011
Final Report: Nerium AD clinical trial is completed. (See Final Report as well as clinical trial video.)

June, 2011
Presentation Annual Meeting of the American Society of Clinical Oncology (ASCO)

April, 2011
ST&T Research conducts NeriumAD Clinical Study.
Clinical research for NeriumAD product safety, efficacy, and dermal application was initiated with ST&T Research.